FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS


Date/App# patent app List of recent Mammal-related patents
07/24/14
20140207251
 Bio-selective surface textures patent thumbnailnew patent Bio-selective surface textures
Bio-selective textured surfaces are described which mediate foreign body response, bacterial adhesion, and tissue adhesion on devices implanted in a mammalian body. Hierarchical levels of texture, some capable of establishing a wenzel state others a cassie state, are employed to interface with living structures, either to promote or discourage a particular biological response/interaction.
07/24/14
20140206931
 Methods for predicting mammalian embryo viability patent thumbnailnew patent Methods for predicting mammalian embryo viability
The invention provides methods and systems for assessing the developmental potential of mammalian embryos. The method of the invention comprises taking measurements of cytoplasmic movements in the embryo and/or periodic changes in the shape of the embryo at the single cell stage..
07/24/14
20140206836
 Novel n- and c-terminal substituted antagonistic analogs of gh-rh patent thumbnailnew patent Novel n- and c-terminal substituted antagonistic analogs of gh-rh
There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 1) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.
07/24/14
20140206770
 Androgen receptor-dependent gene expression control patent thumbnailnew patent Androgen receptor-dependent gene expression control
Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (lsd1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (lsd1) in a mammal.. .
07/24/14
20140206762
 Compositions and methods of use of phorbol esters patent thumbnailnew patent Compositions and methods of use of phorbol esters
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease.
07/24/14
20140206754
 Methods and materials for reducing the severity of viral infections patent thumbnailnew patent Methods and materials for reducing the severity of viral infections
This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided..
07/24/14
20140206751
 Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules patent thumbnailnew patent Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
Methods for producing interfering rna molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of hiv, are also provided..
07/24/14
20140206718
 Method of enhancing lysosomal alpha-galactosidase a patent thumbnailnew patent Method of enhancing lysosomal alpha-galactosidase a
A method of enhancing the activity of lysosomal α-galactosidase a (α-gal a) in mammalian cells and for treatment of fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.. .
07/24/14
20140206634
 Natural composition to decrease effects of a high fat diet patent thumbnailnew patent Natural composition to decrease effects of a high fat diet
The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable.
07/24/14
20140206612
 Oral insulin therapies and protocol patent thumbnailnew patent Oral insulin therapies and protocol
Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
07/24/14
20140206572
new patent Ovarian markers of follicular maturity and uses thereof
The present invention relates to field of fertility. The invention identifies biological ovarian markers from follicular cells, from follicular fluid, from cumulus cells and from oocytes which are indicative of follicular maturity in mammals.
07/24/14
20140206546
new patent Methods and compositions for single cell expression profiling
Methods of obtaining a single cell expression profile from a target mammalian cell are provided. Aspects of the methods include contacting a cellular sample which includes the target mammalian cell with a packaged viral barcoded trans-splicing library including a plurality of barcoded trans-splicing constructs under transduction conditions, where a barcoded trans-splicing construct includes a trans-splicing element linked to a barcode element.
07/24/14
20140206102
new patent Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
This document provides methods and materials for detecting c9orf72 hexanucleotide (ggggcc) (seq id no: 3) repeat expansion positive (c9+) frontotemporal lobar degeneration or c9+ amyotrophic lateral sclerosis. For example, methods and materials related to using anti-(gp)8 (seq id no: 2) antibodies to identify mammals (e.g., humans) having c9+ ftld or c9+ als are provided..
07/24/14
20140206038
new patent Cell culture improvements
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture..
07/24/14
20140206004
new patent Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays
This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
07/24/14
20140205994
new patent Methods, devices, kits and compositions for detecting roundworm, whipworm, and hookworm
Methods, devices, kits and compositions for detecting the presence or absence of one or more helminthic coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm, whipworm and/or hookworm in a fecal sample from a mammal and may also be able to distinguish between one or more helminth infections.
07/24/14
20140205709
new patent Production of food and beverage products from barley grain
The present invention provides a process for producing a food ingredient or beverage ingredient. The present invention also provides a process for producing food product or beverage product.
07/24/14
20140205623
new patent Protein-based streptococcus pneumoniae vaccines
Vaccine compositions and methods for protecting a mammalian subject against infection with s. Pneumoniae are disclosed.
07/24/14
20140205616
new patent Compositions and methods for the diagnosis and treatment of tumor
The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.. .
07/24/14
20140205574
new patent Use of stem cells or progenitor cells to treat, delay, prevent, or repair tearing of cruciate ligaments
Methods for treating a partial or complete rupture of cranial cruciate ligament (crcl) damage and for preventing or delaying crcl damage with or without synovitis in dogs are disclosed. For example, this document provides methods for using stem cells and/or progenitor cells to prevent or reduce the likelihood of crcl rupture in the contralateral leg of mammals, especially dogs, diagnosed with crcl rupture, as well as methods for using stem cells and/or progenitor cells to treat, delay or prevent complete crcl rupture in mammals, especially dogs, diagnosed as having a partial crcl rupture..
07/24/14
20140205538
new patent Vaccines targeting cellular death receptors
The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family.
07/17/14
20140201856
Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
07/17/14
20140201854
Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
07/17/14
20140200573
Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
Methods and apparatus are provided, for selective destruction or temporary disruption of nerves and/or conduction pathways in a mammalian body for the treatment of pain and other disorders. Apparatus comprises catheters having electrodes for targeting and affecting nerve tissue at a cellular level to reversible and irreversible nerve portion and incapacitation..
07/17/14
20140200547
Method for altering drug pharmacokinetics based on medical delivery platform
A method for directly delivering whereby a substance is introduced into an intradermal space within mammalian skin which involves administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm. The outlet is inserted into the skin to a depth of between 0.3 mm and 2 mm such that the delivery of the substance occurs at a depth between 0.3 mm and 2 mm..
07/17/14
20140200503
Systems, devices, and methods for isolation of stem cells
The present disclosure relates, in some embodiments, to apparatus, systems, methods, and compositions for purifying cells (e.g., adipocytes, stem cells) from mammalian tissues (e.g., adipose tissues). For example, the present disclosure relates to apparatus, systems, methods, and compositions for purifying and/or preserving adipocytes and/or stem cells from fat tissue of a mammalian subject according to some embodiments..
07/17/14
20140200428
Impedance devices and methods of using the same to obtain luminal organ measurements
Impedance devices and methods of using the same to obtain luminal organ measurements. In at least one embodiment of an impedance device of the present disclosure, the impedance device comprises an elongated body having a distal body end, and a first electrode located along the elongated body at or near the distal body end, the first electrode configured to obtain one or more conductance values within a mammalian luminal organ within an electric field, wherein a measured parameter of the mammalian luminal organ can be calculated based in part upon the one or more conductance values obtained by the first electrode..
07/17/14
20140200331
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the ch1 and/or cl domains, amino acid modifications in the vh and/or vl domains or a combination thereof.
07/17/14
20140200329
Bisaminoethanethiol-targeting ligand conjugates and compositions
The invention provides, in a general sense, a new labeling strategy employing 99mtc chelated with ethylenedicysteine (ec). Ec is conjugated with a variety of ligands and chelated to 99mtc for use as an imaging agent for tissue-specific diseases.
07/17/14
20140200251
Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
Where r1 is l1c(o)ot or l1c(o)ol2c(o)ot; r2 is a substituted or unsubstituted c1-c10 alkyl, c2-c10 alkenyl, or c2-c10 alkynyl, or r1; n is an integer from 0 to 5; each r3 is independently halogen or r2; l1 and l2 are each independently a bond, a substituted or unsubstituted c1-c10 alkylene, c2-c10 alkenylene, or c2-c10 alkynylene; and t is h, a substituted or unsubstituted c1-c10 alkyl, c2-c10 alkenyl, or c2-c10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (i) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition..
07/17/14
20140200217
Smoothened antagonism for the treatment of hedgehog pathway-related disorders
The invention provides methods for modulating, e.g., antagonizing, the activity of the hedgehog signaling pathway, and for treating hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as ptch loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or gli gain-of-function by administering to a mammal combinations of smoothened inhibitors (e.g., a compound of formula i, formula ii, or formula iii, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), gli inhibitors, and/or phosphatidylinositol 3-kinase (pi3k) inhibitors..
07/17/14
20140200190
Novel galactoside inhibitors of galectins
Compounds having an effect as i.a. Galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, wherein the galectin is preferably a galectin-3.
07/17/14
20140200163
Multiplexed genetic reporter assays and compositions
The invention provides methods for determining the activity of a plurality of nucleic acid regulatory elements. These methods may facilitate, e.g., the systematic reverse engineering, and optimization of mammalian cis-regulatory elements at high resolution and at a large scale.
07/17/14
20140200149
Methods and compositions for identification of source of microbial contamination in a sample
Herein are described 1058 different bacterial taxa that were unique to either human, grazing mammal, or bird fecal wastes. These identified taxa can serve as specific identifier taxa for these sources in environmental waters.
07/17/14
20140199766
Transgenic system for reversibly immortalizing mammalian quiescent cells
A transgene for endowing human quiescent cells from primary cultures with exogenously inducible telomere length homeostasis and cell cycle traverse is described. The transgene includes at least three promoter sequences; a g1-specific rna interference sequence which is operably linked downstream of a first promoter sequence; a telomere length maintenance gene sequence which is operably linked downstream to a second promoter sequence; a scaffold/matrix attachment region (s/mar) element positioned downstream in frame with said telomere length maintenance gene sequence and an exogenously-inducible transcriptional regulation system.
07/17/14
20140199417
Antihistamines combined with dietary supplements for improved health
The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as l-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected b vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans..
07/17/14
20140199408
Therapeutic stem cell nutrient composition and uses thereof
The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in l form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free l-amino acids in which the molar ratio of the free l-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid..
07/17/14
20140199372
Microbial growth factors
Disclosed are methods of cultivating or isolating a microorganism using one or more quinones as growth factors. Also disclosed are methods of treating a mammalian species with deficiency in symbionts using such compounds..
07/17/14
20140199285
Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs
A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a dna sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(β-d-arabinofuranosyl)-2-fluoroadenine (f-araa)..
07/17/14
20140199281
Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.. .
07/17/14
20140199270
Methods and compositions to reduce fat gain, promote weight loss in mammals
The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, ldl, triglycerides, blood glucose, leptin and c-reactive protein levels and increase in hdl and serotonin levels in an mammal. The lepticore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications.
07/17/14
20140199255
Use of natural or naturally derived polyesters as hair fixatives
The invention relates to a use of a composition comprising at least one naturally derived poly(lactic acid) film-forming polymer and a carrier for styling mammalian hair.. .
07/10/14
20140194612
Immunosuppression compound and treatment method
A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed ctla-4 mrna region identified by seq id no: 22 in seq id no: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mrna of the subject.
07/10/14
20140194521
Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment..
07/10/14
20140194520
Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a ph of greater than about 10 or less than about 4.5 with low buffer capacity.
07/10/14
20140194500
Methods for treating of sars
Provided is a method of treating sars in mammals. The method includes administering a therapeutically effective amount of at least one composition selected from the group consisting of myricetin, scutellarein and a pharmaceutically acceptable salt thereof to a mammal in need of treatment of sars diseases to suppress the activities of sars coronavirus helicase..
07/10/14
20140194462
Alpha-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
The present application is related to compounds represented by formula i, which are novel allosteric modulators of α7nachr. The application also discloses the treatment of disorders that are responsive to modulation of acetylcholine action on α7nachr in a mammal by administering an effective amount of a compound of formula i..
07/10/14
20140194408
Heteroaryl pyridone and aza-pyridone compounds
Heteroaryl pyridone and aza-pyridone compounds of formula i are provided, where one or two of x1, x2, and x3 are n, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating immune disorders such as inflammation mediated by btk kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
07/10/14
20140194346
Pasteurellaceae vaccines
The present invention relates to an n-glycosylated protein for treating and/or preventing bacterial pasteurellaceae infection in a mammal or bird, wherein the protein is a pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated n-x-s/t consensus sequence. In addition, the present invention is directed to corresponding pharmaceutical compositions for treating and/or protecting mammals or birds having or being prone to develop a bacterial pasteurellaceae infection.
07/10/14
20140193525
Methods for treating or preventing radiocontrast agent induced kidney injury
Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal.. .
07/10/14
20140193516
Methods for treating glucose metabolic disorders
In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus.
07/10/14
20140193494
Misuse preventative, controlled release formulation
Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation.
07/10/14
20140193483
Therapeutic vaccines for treating herpes simplex virus type-2 infections
The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. Mammals) against viral antigens, including herpes-simplex virus type 2.
07/10/14
20140193480
Topical anti-inflammatory compositions and uses thereof
Disclosed are pharmaceutical compositions and topical formulations thereof that include multiple, phytochemically-active, nutraceutical compounds, and that possess potent anti-inflammatory and extracellular matrix-stabilizing properties both in vitro and in vivo. Also disclosed are prophylactic and therapeutic methods, as well as dosing regimens and medicaments for use in preventing chronic disease, for treating acute or long-term inflammatory-mediated conditions in affected or at-risk subjects, and for stabilizing one or more components of the mammalian extracellular matrix..
07/10/14
20140193479
Compositions and methods for treatment of mammalian skin
Compositions useful for treatment of a wide range of skin disorders including: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, and radiation-induced burns. In some embodiments the treatments comprise contacting human or other mammalian skin with a composition according to the disclosure.
07/10/14
20140193478
Compositions and methods for treatment on mammalian skin
Compositions useful for treatment of a wide range of skin disorders including: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, and radiation-induced burns. In some embodiments the treatments comprise contacting human or other mammalian skin with a composition according to the disclosure.
07/10/14
20140193458
Method of vaccination comprising a histone deacetylase inhibitor
A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity..
07/10/14
20140193430
Compositions and methods for regulating nk cell activity
The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of nk cells and allow a potentiation of nk cell cytotoxicity in mammalian subjects.
07/10/14
20140193408
Soluble proteins for use as therapeutics
The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having vh, ch1, ch2, and ch3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the vh region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a vl and cl region; and (d) a monovalent region of a mammalian binding molecule fused to the vl region; characterised in that each pair of vh and vl cdr sequences has specificity for an antigen, such that the total valency of said soluble protein is six.
07/10/14
20140193384
Use of lactobacillus for liver protection
A method for liver protection of a mammal is provided and includes administering an effective amount of isolated lactobacillus plantarum cmu995 thereto. Providing a new use of lactobacillus plantarum cmu995, which is deposited at the food industry research and development institute (firdi) in taiwan under accession number bcrc 910472 and in the german collection of microorganisms and cell cultures (dsmz) under accession number dsm 23780..
07/10/14
20140193382
Endogenous expression of hla-g and/or hla-e by mesenchymal cells
Methods and compositions are provided for the identification and isolation of mammalian hla-g+ msc, hla-e+ msc, or hla-g+/hla-e+ msc. The methods of the invention provide a means to obtain enriched hla-g+ msc, hla-e+ msc, or hla-g+/hla-e+ msc populations..
07/10/14
20140193332
Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.. .
07/10/14
20140193330
Compositions and methods for multimodal imaging
There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent from the carrier.
07/10/14
20140192617
System for acquiring seismic data in a marine environment, using seismic streamers coupled to means for detecting and/or locating marine mammals
Discloses herein is a system of acquiring seismic date in a marine environment, which includes: seismic streamers towed by a vessel; and means for detecting and/or locating marine mammals, characterised in that said marine mammal detection and/or location means are secured to said seismic streamers.. .
07/03/14
20140189897
Transgenic animals capable of being induced to delete senescent cells
This document relates to methods and materials involved in the removal of senescent cells within a mammal. For example, transgenic non-human animals that can be induced to delete senescent cells are provided..
07/03/14
20140188154
Electronic device for weight control
Orally administrable polymer-carrying units for expanding in a stomach of a mammal to fill a space in the stomach, the polymer-carrying units including: a carrier; a plurality of polymer molecules expandable in aqueous solutions, releasably coupled to the carrier; and means for selectively decoupling the polymer molecules from the carrier so that the polymer molecules and carrier are released in the stomach, are provided.. .
07/03/14
20140188024
Device and method for applying pressure to mammalian limb
A therapeutic pressure strap for applying pressure across a muscle or muscle groups on a mammalian limb is described. The strap is particularly well suited for treating “tennis elbow”.
07/03/14
20140187640
N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
Methods and compositions comprising n-acetylcysteine amide (nac amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of nac amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione..
07/03/14
20140187612
Method of modulating integrin mediated cellular activity and agents useful for same
An isolated nucleic acid encodes a polypeptide for inhibiting growth of a cancer cell. The amino acid sequence defines a binding domain of a β integrin subunit for erk2 map kinase, the binding domain comprising an intervening, centrally located amino acid linker sequence that links opposite terminal end amino acid sequence regions of the binding domain together and is non-essential for binding of the map kinase to the binding domain.
07/03/14
20140187602
Anti-sense oligonucleotides targeted against exon 9 of il-23r alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases
The present invention relates to anti-sense oligonucleotides (aons) used to induce exon 9 skipping in il-23rαgene. Exon 9 skipping of the il23rα gene ultimately causes specific induction of a novel soluble truncated il-23rα (Δ9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (glkegsyc) at its c-terminus end as a result of frame-shift.
07/03/14
20140187584
Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnfalpha levels
Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of tnfα in a mammal..
07/03/14
20140187505
Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
Disclosed is the use of a cardiac glycoside to decrease or inhibit the secretion of proinflammatory mediators in the treatment of disease conditions characterized by elevated levels of the proinflammatory mediator. The cardiac glycoside is administered to a mammalian subject in need of such treatment, and dosage is adjusted to the mass of the recipient and the need of the recipient to reduce or inhibit the level of the proinflammatory mediator.
07/03/14
20140187490
Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient.
07/03/14
20140187483
Glp-1 and methods for treating diabetes
The present invention relates to use of glp-1 or a related molecule having glp-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday”.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3055

3105

1 - 1 - 74